5 February 2024
Kromek Group
plc
("Kromek"
or the "Group")
Kromek granted £1.3m under
Horizon Europe guarantee scheme
New joint project to develop
AI-powered radiation sensor
Kromek Group
plc (AIM: KMK), a leading developer of radiation and bio-detection
technology solutions for the advanced imaging and CBRN detection
segments, announces that it has been awarded a grant of £1.3m under
the UK Research and Innovation ("UKRI") Horizon Europe guarantee
scheme to participate in the Intelligent Radiation Sensor Readout
System ("i-RASE") project to develop a new class of radiation
sensor powered by artificial intelligence ("AI").
The i-RASE project, to be led by DTU
Space, is a collaboration between industrial and academic partners
in Denmark, Germany, Norway and Italy to design, build and test a
new class of radiation sensor based on cadmium zinc telluride
("CZT") and other advanced technologies. The aim is to develop a
radiation detector that leverages the latest developments in AI to
facilitate the retrieval of comprehensive information on incident
radiation to improve measurement accuracy and speed, while
increasing energy efficiency. This offers transformational
potential for various radiation applications, such as medical
imaging, industrial inspection, scientific space instrumentation
and environmental monitoring. The project will start on 1 March
2024 and will run for a period of 48 months.
i-RASE is part of the European
Union's Horizon Europe programme, with which the UK is associated,
and is designed to facilitate collaboration and strengthen the
impact of research and innovation in developing, supporting and
implementing EU policies while tackling global challenges. Kromek
is receiving £1.3m from UKRI, on behalf of the UK government's
Department for Science, Innovation & Technology, to participate
in the project.
Arnab Basu, CEO of Kromek, said: "With the increasing prevalence of AI, Kromek has for
several years been exploring the application of machine learning
across its technologies, and has generated some significant IP in
this area. This collaboration brings an opportunity to enhance our
expertise by working with field-leading partners throughout Europe,
and ultimately lead to improved capabilities of our products across
our market segments."
For
further information, please contact:
Kromek Group plc
|
|
Arnab Basu, CEO
Paul Farquhar, CFO
|
+44 (0)1740 626 060
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and
Broker)
|
|
Geoff Nash/Giles Balleny/Seamus
Fricker - Corporate Finance
Tim Redfern - ECM
Michael Johnson/Tamar Cranford-Smith
- Sales
|
+44 (0)20 7220 0500
|
Gracechurch Group (Financial PR)
|
|
Harry Chathli/Claire Norbury/Henry
Gamble
|
+44 (0)20 4582 3500
|
|
|
Kromek Group plc
Kromek Group plc is a leading
developer of radiation detection and bio-detection technology
solutions for the advanced imaging and CBRN detection segments.
Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing
the quality of life through innovative detection technology
solutions.
The advanced imaging segment
comprises the medical (including CT and SPECT), security and
industrial markets. Kromek provides its OEM customers with detector
components, based on its core cadmium zinc telluride (CZT)
platform, to enable better detection of diseases such as cancer and
Alzheimer's, contamination in industrial manufacture and explosives
in aviation settings.
In CBRN detection, the Group
provides nuclear radiation detection solutions to the global
homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced
scintillation and solid-state readout technology, are primarily
used to protect critical infrastructure, events, personnel and
urban environments from the threat of 'dirty
bombs'.
The Group is also developing
bio-security solutions in the CBRN detection segment. These consist
of fully automated and autonomous systems to detect a wide range of
airborne pathogens.
Kromek is listed on AIM, a market of
the London Stock Exchange, under the trading symbol
'KMK'.